# Clinical Trials Data KRAS - Document 10

# Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT02135757

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with a histologically confirmed diagnosis of mCRC.\n\* Immunohistochemical evidence of EGFR expression.\n\* ECOG performance status of 0, 1 or 2.\n\* Patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens\n\* Patients with a wt KRAS scheduled to receive panitumumab as a single agent for the third-line treatment of mCRC or patients with a mt KRAS scheduled to receive SOC for third-line treatment of mCRC.\n\* Signed and dated IRB-approved informed consent document.\n\* Ability to read and understand English or French.\n\* 18 years of age or older.\n\nExclusion Criteria:\n\n\* Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with chemotherapy-refractory metastatic colorectal cancer from participating hospitals in Quebec.",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
A patient with \*\*any\*\* KRAS mutation (either a wild-type "wt" KRAS or a mutant "mt" KRAS) \*could\* be eligible for this trial. The inclusion criteria specifically mention both:  
  
\* \*\*wt KRAS:\*\* These patients are eligible if they are scheduled to receive panitumumab.  
\* \*\*mt KRAS:\*\* These patients are eligible if they are scheduled to receive standard of care (SOC) for third-line treatment.  
  
Therefore, simply having a KRAS mutation doesn't disqualify a patient. The type of KRAS mutation and planned treatment determine eligibility.